COVID-19的临床实验室评估
本文综述了COVID-19临床实验室检测的作用,包括核酸检测和基因测序作为病原学证据、特异性抗体动态监测补充假阴性、感染第一周推荐抗原检测,以及随疾病进展多项实验室指标异常变化,并指出高危患者应动态监测以预警重症。
要点
- 核酸检测或基因测序可作为临床疑似病例的病原学证据。
- 特异性抗体(IgM、IgA、IgG)动态监测可补充核酸假阴性。
- 感染第一周推荐抗原检测,与高病毒载量相关。
核心结论
- 临床实验室检测在COVID-19诊断和评估疾病进展中发挥重要作用。
主要发现
- 从中度到重度和危重病例,白细胞、中性粒细胞和中性粒细胞-淋巴细胞比值升高,淋巴细胞进行性下降但过度活化。
- LDH、AST、ALT、CK、高敏肌钙蛋白I和尿素也进行性升高,D-二聚体升高是重症指标和死亡的独立危险因素。
- 炎症生物标志物和细胞因子如CRP、SAA、铁蛋白、IL-6和TNF-α逐渐升高。
关键数值与推荐
- 核酸扩增检测或基因测序可作为临床疑似病例COVID-19诊断的病原学证据。
- 特异性抗体(IgM、IgA和IgG)动态监测是SARS-CoV-2核酸假阴性检测的有效补充。
- 推荐在感染第一周进行抗原检测以识别SARS-CoV-2,与高病毒载量相关。
临床怎么用
- 对老年人和有基础疾病(心血管疾病、糖尿病、慢性呼吸系统疾病、高血压、肥胖和癌症)等高危重症COVID-19患者应动态监测,有助于预警严重疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19, caused by SARS-CoV-2, is a highly infectious disease, and clinical laboratory detection has played important roles in its diagnosis and in evaluating progression of the disease. Nucleic acid amplification testing or gene sequencing can serve as pathogenic evidence of COVID-19 diagnosing for clinically suspected cases, and dynamic monitoring of specific antibodies (IgM, IgA, and IgG) is an effective complement for false-negative detection of SARS-CoV-2 nucleic acid. Antigen tests to identify SARS-CoV-2 are recommended in the first week of infection, which is associated with high viral loads. Additionally, many clinical laboratory indicators are abnormal as the disease evolves. For example, from moderate to severe and critical cases, leukocytes, neutrophils, and the neutrophil-lymphocyte ratio increase; conversely, lymphocytes decrease progressively but are over activated. LDH, AST, ALT, CK, high-sensitivity troponin I, and urea also increase progressively, and increased D-dimer is an indicator of severe disease and an independent risk factor for death. Severe infection leads to aggravation of inflammation. Inflammatory biomarkers and cytokines, such as CRP, SAA, ferritin, IL-6, and TNF-α, increase gradually. High-risk COVID-19 patients with severe disease, such as the elderly and those with underlying diseases (cardiovascular disease, diabetes, chronic respiratory disease, hypertension, obesity, and cancer), should be monitored dynamically, which will be helpful as an early warning of serious diseases.
引用
- Chen Z, Xu W, Ma W, et al. Clinical laboratory evaluation of COVID-19. Clin Chim Acta. 2021. PMID: 33939954. doi:10.1016/j.cca.2021.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。